Neumora Therapeutics IPO Presentation Deck

Navacaprant: KOR Antagonism has Potential for Broad Neuropsychiatric Impact Potential to be first novel mechanism approved in MDD in decades Pharmacologic Profile Selective kappa opioid receptor (KOR) antagonist Greater than 300-fold selectivity of KOR over mu opioid receptor (MOR) and supports 90% receptor occupancy coverage Pathophysiology The KOR/dynorphin system is a well-characterized pathway known to modulate depression, anhedonia, and anxiety - Exposure to stress leads to elevated expression of the KOR ligand dynorphin, resulting in depressive and anxiety-related symptoms Blocking this action via KOR antagonists has antidepressant- and anxiolytic-like effects In animal models, KOR agonists induce depressive and anxiogenic behaviors (including drug-seeking behaviors), whereas KOR antagonists exert antidepressant and anxiolytic effects In humans, KOR agonists induce dysphoric, anxiogenic, and depressive effects Drug Profile Oral, once-daily, 80 mg dose Strong Biological Rationale KOR/dynorph in are important regulators of stress- induced alterations in reward processing, mood states and cognition Strong IP Protection Expect exclusivity through 2041, based on composition of matter protection and estimated patent term extension Dynorphin is released -O in response to stress and activates KOR When KOR is activated, these neurotransmitters are modulated Dopamine GABA KOR Antagonist of KOR Gi . Serotonin Dysregulation of these neurotransmitters can lead to changes in circuits involved in: . Depression. Anhedonia • Anxiety Cognitive impairment NMRA-140 Neuron Glutamate Endogenous pathways Obstructed in disease Drug impact Confidential 8

View entire presentation